SAN DIEGO, April 17, 2017 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company
focused on developing novel, small molecule drugs across multiple
therapeutic areas, today announced three data presentations on
etrasimod (APD334) at ASPET 2017 at Experimental Biology
(EB). The conference is taking place April 22-26 at McCormick Place Convention Center
in Chicago, IL.
The presentations encompass preclinical data highlighting the
potent and selective immunomodulatory effects of etrasimod in
inflammatory bowel disease (IBD), including ulcerative colitis
(UC).
The following abstracts will be presented:
Title: Etrasimod, a Novel Sphingosine-1-Phosphate Receptor
(S1PR1) Modulator, Lacks Functional Activity at S1P2
Receptors
Day of presentation: Sunday, April 23, 2017
Abstract Number: 6502
Poster Session Title: Cell Signaling and Cancer Therapeutics
Poster Board Number: D148
Location: McCormick Place Convention Center, Hall F
Title: Etrasimod (APD334), an Oral, Next-Generation
Sphingosine-1-Phosphate Receptor Modulator Inhibits the Development
of Colitis in Lymphoid-Null Mice Injected with Colitogenic CD4+ T
Cells
Day of presentation: Tuesday,
April 25, 2017
Abstract Number: 6337
Poster Session Title: Drug Discovery and Development:
Immunomodulation and Inflammation
Poster Board Number: D125
Location: McCormick Place Convention Center, Hall F
Title: Functional Activity of Etrasimod and a Diverse Panel
of Sphingosine-1-Phosphate Receptor (S1PR1) Modulators at S1P4
Receptors
Day of presentation: Tuesday, April 25, 2017
Abstract Number: 6545
Poster Session Title: Drug Discovery and Development:
Immunomodulation and Inflammation
Poster Board Number: D126
Location: McCormick Place Convention Center, Hall F
About Arena Pharmaceuticals
Arena Pharmaceuticals is a
biopharmaceutical company focused on developing novel, small
molecule drugs with optimized receptor pharmacology designed to
deliver broad clinical utility across multiple therapeutic areas.
Our proprietary pipeline includes potentially first- or
best-in-class programs for which we own global commercial
rights. Our three most advanced investigational clinical
programs are ralinepag (APD811) in Phase 2 evaluation for pulmonary
arterial hypertension (PAH), etrasimod (APD334) in Phase 2
evaluation for multiple autoimmune indications, and APD371 in Phase
2 evaluation for the treatment of pain associated with Crohn's
disease. In addition, Arena has collaborations with the following
pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc.
(commercial stage), Axovant Sciences (Phase 2 candidate), and
Boehringer Ingelheim International GmbH (preclinical
candidate).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. Such forward-looking statements include
statements about the upcoming presentation; Arena's focus, and the
potential of its programs and collaborations. For such statements,
Arena claims the protection of the Private Securities Litigation
Reform Act of 1995. Actual events or results may differ materially
from Arena's expectations. Factors that could cause actual results
to differ materially from the forward-looking statements include
those disclosed in Arena's filings with the Securities and Exchange
Commission. These forward-looking statements represent Arena's
judgment as of the time of this release. Arena disclaims any intent
or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Contact: Arena Pharmaceuticals, Inc.
Kevin R. Lind, Chief Financial
Officer
klind@arenapharm.com
858.210.3636
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-announces-multiple-presentations-at-aspet-2017-at-experimental-biology-300440006.html
SOURCE Arena Pharmaceuticals, Inc.